Skip to main content

Advertisement

Table 4 Utility decrements and cycle rates of adverse events

From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

  Utility decrements Cycle rates (%)
Ustekinumab [23,24,25] Adalimumab [40, 41, 48, 51, 52] Vedolizumab [39, 53]
Serious infection − 0.52 [54] 0.34 0.32 0.32
Tuberculosis − 0.55 [55] 0.00 0.00 0.00
Lymphoma − 0.20 [56] 0.00 0.00 0.00
Hypersensitivity − 0.11 [57] 0.01 0.00 0.00
Skin reactions − 0.03 [58] 0.75 10.37 0.59